Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma

Maredia, Hasina; Simkin, Daren J.; Soni, Abha; Loss, Manisha J.

doi:10.1111/ijd.14701

Cited by 7 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 57 studies were excluded they involved a different patient population (ie, not drug‐induced porokeratosis, n = 33), incorrect study design (n = 10), wrong interventions (n = 6), and wrong outcomes (n = 6). After full‐text review, 25 studies were included for analysis 6,8,10,14‐35 …”

Section: Resultsmentioning

confidence: 99%

Drugs associated with development of porokeratosis: A systematic review

Mufti

Sachdeva

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Porokeratosis is a rare disorder characterized by atrophic macules or patches, with a well‐defined ridge‐like hyperkeratotic border called cornoid lamella. Although the exact pathogenesis is unknown, drug associated cases have recently been reported in the literature. As such, we systematically reviewed and identified drugs associated with drug‐induced porokeratosis, their resultant effects, and whether there was a casual relationship between the use of a drug and the development of porokeratosis. We searched for articles which reported drug‐induced porokeratosis in MEDLINE and Embase in June 2020. After full‐text review, 25 studies were included for analysis. We identified 26 patients with drug‐induced porokeratosis. The most common therapies associated with development of porokeratosis is biologic use, phototherapy, and radiotherapy. The most common clinical variants were the disseminated superficial or actinic types (60%), which occurred in psoriasis patients undergoing phototherapy, and eruptive disseminated type (24%) which occurred in the context of biologic therapies. The Naranjo score ranged from possible to probable for the identified treatments. Clinicians should consider drug reactions as possible triggering events for porokeratosis, especially for patients taking biologics, phototherapy, and radiotherapy. Large‐scale studies are required to confirm our findings and further explore the pathogenesis for drug‐induced porokeratosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Drugs associated with development of porokeratosis: A systematic review

Mufti

Sachdeva

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…However, the literature on porokeratosis about pembrolizumab is limited. 2 Porokeratosis is a rare epidermal keratinisation disorder, which may be a rare complication of biological therapy 6 and phototherapy especially in individuals with underlying malignancies. 4 However, the pathway that leads to this process remains unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Considering the time of onset, the patient's porokeratosis may be caused by pembrolizumab, although there was no hyperkeratotic plaque at the first hospitalisation. However, the literature on porokeratosis about pembrolizumab is limited 2 …”

Section: Discussionmentioning

confidence: 99%

“…However, cutaneous eruptions are one of the most common immune‐related adverse events, including lichenoid reactions, 1 erythema multiforme, psoriasiform reactions, vitiligo, porokeratosis, 2 bullous pemphigoid, dermatomyositis and oral mucosal changes, observed in about 40% of patients 3 . Even though most symptoms are mild, the severity of symptoms varies from mild to severe.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pembrolizumab associated Stevens–Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma

Zhang

et al. 2021

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…1,2 Two cases of porokeratosis occurring during treatment with PD1 inhibitor have already been described. 3,4 Here, we describe a case of porokeratosis that developed following the administration of nivolumab with characteristic histopathologic findings of a cutaneous irAE associated with PD1 inhibitors.…”

mentioning

confidence: 99%